| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric/humanized hybrid (rat/human) |
| Target | CD3E |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6448H9954N1718O2016S42 |
| Molar mass | 145145.09 g·mol−1 |
  (what is this?) (verify) | |
Otelixizumab, also known as TRX4, is a monoclonal antibody,[1] which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories.[2][3]
- ^ Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H (February 1993). "The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties". European Journal of Immunology. 23 (2): 403–11. doi:10.1002/eji.1830230216. PMID 8436176. S2CID 25876507.
- ^ "Windhover Information "GSK buys rights to Tolerx's diabetes antibody otelixizumab"". Archived from the original on 2011-07-18. Retrieved 2009-04-13.
- ^ "TolerRx Inc., of Cambridge, Mass., entered an agree- ment with Abbott Park, Ill.-based Abbott Laboratories for the manufacturing of TolerRx's TRX4 monoclonal antibody" (PDF). Bioworld Today. Vol. 16, no. 228. Thomson Bioworld. 20 November 2005. p. 6. Retrieved 2 December 2009.